Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599047 | 0.94 | AKR1C3 (0.65) | AKR1C3HRH4KMT2AMEN1NPC1 | |
| SCHEMBL17954133 | 0.91 | AKR1C3 (0.73) | AKR1C3HRH4KMT2AMEN1NPC1 | |
| SCHEMBL16598942 | 0.90 | AKR1C3 (0.69) | AKR1C3HRH4KMT2AMEN1NPC1 | |
| SCHEMBL17954140 | 0.88 | KMT2A (0.73) | AKR1C3HRH4KMT2AMEN1NPC1 | |
| SCHEMBL16598573 | 0.87 | KDM4E (0.71) | AKR1C3HRH4KMT2AMEN1NPC1 | |
| SCHEMBL16598630 | 0.87 | AKR1C3 (0.70) | AKR1C3HRH4KMT2AMEN1NPC1 | |
| SCHEMBL16599077 | 0.86 | AKR1C3 (0.71) | AKR1C3HRH4KMT2AMEN1NPC1 | |
| SCHEMBL16598772 | 0.85 | AKR1C3 (0.65) | AKR1C3HRH4KMT2AMEN1NPC1 | |
| SCHEMBL16598809 | 0.83 | MEN1 (0.80) | AKR1C3HRH4KMT2AMEN1NPC1 | |
| SCHEMBL17954128 | 0.82 | KMT2A (0.60) | AKR1C3HRH4KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214951-A1 | EBI2 MODULATORS | BIRC2, HAVCR2, MAVS | AKR1C3 3119/4885HRH4 3590/4885KMT2A 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.